Global and United States Messenger RNA Vaccines and Therapeutics Market Report & Forecast 2024-2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global and United States Messenger RNA Vaccines and Therapeutics Market Report & Forecast 2024-2034
An mRNA vaccine is a vaccine that uses a molecular copy of messenger RNA to generate an immune response. [1] Such vaccines deliver antigen-coding mRNA molecules into immune cells, which use the designed mRNA as a template to build foreign proteins normally produced by pathogens such as viruses or cancer cells. These protein molecules stimulate an adaptive immune response, teaching the body to recognize and destroy the corresponding pathogen or cancer cell. mRNA is composed of RNA encapsulated in lipid nanoparticles, which protect the RNA strand and facilitate its uptake into cells. Reactogenicity, the propensity of the vaccine to produce adverse reactions, was similar to that of traditional non-RNA vaccines. People prone to autoimmune reactions may experience adverse reactions to messenger RNA vaccines. Compared with traditional vaccines, mRNA vaccines have the advantages of being easy to design, fast in production, low in cost, capable of inducing cellular and humoral immunity, and not interacting with genomic DNA.
Market Analysis and InsightsGlobal and United States Messenger RNA Vaccines and Therapeutics Market
This report focuses on global and United States Messenger RNA Vaccines and Therapeutics market, also covers the segmentation data of other regions in regional level and county level.
The global Messenger RNA Vaccines and Therapeutics revenue was US$ 9800 million in 2024 and is forecast to a readjusted size of US$ 24570 million by 2034 with a CAGR of 12.6% during the review period (2024-2034).
In United States the Messenger RNA Vaccines and Therapeutics revenue is expected to grow from US$ million in 2024 to US$ million by 2034, at a CAGR of % during the forecast period 2024-2034.
The global key players of Messenger RNA Vaccines and Therapeutics include BioNTech, Moderna, CureVac, Pfizer, Glaxo Smith Kline's, Daiichi Sankyo Company, Intellia Therapeutics, Arcturus Therapeutics and Emmy Vaccine, etc. The global five biggest players hold a share of % in 2024.
Global Messenger RNA Vaccines and Therapeutics Scope and Market Size
Messenger RNA Vaccines and Therapeutics market is segmented in regional and country level, by players, by Type and by Application. Companies, stakeholders, and other participants in the global Messenger RNA Vaccines and Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2018-2034.
For United States market, this report focuses on the Messenger RNA Vaccines and Therapeutics market size by players, by Type and by Application, for the period 2018-2034. The key players include the global and local players, which play important roles in United States.
BioNTech
Moderna
CureVac
Pfizer
Glaxo Smith Kline's
Daiichi Sankyo Company
Intellia Therapeutics
Arcturus Therapeutics
Emmy Vaccine
CSPC
CanSino
Fosun Pharma
Segment by Type
Self-amplifying
Conventional Non-amplifying
Cancer
Infectious Diseases
Autoimmune Diseases
Others
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter 1Introduces Messenger RNA Vaccines and Therapeutics definition, global market size, United States market size, United States percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Messenger RNA Vaccines and Therapeutics companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger and acquisition information, etc.
Chapter 5Revenue of Messenger RNA Vaccines and Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 6Americas by type, by application and by country revenue for each segment.
Chapter 7EMEA by type, by application and by region, revenue for each segment.
Chapter 8China by type, by application revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Messenger RNA Vaccines and Therapeutics revenue, gross margin and recent development, etc.
Chapter 11Analyst's Viewpoints/Conclusions
Market Analysis and InsightsGlobal and United States Messenger RNA Vaccines and Therapeutics Market
This report focuses on global and United States Messenger RNA Vaccines and Therapeutics market, also covers the segmentation data of other regions in regional level and county level.
The global Messenger RNA Vaccines and Therapeutics revenue was US$ 9800 million in 2024 and is forecast to a readjusted size of US$ 24570 million by 2034 with a CAGR of 12.6% during the review period (2024-2034).
In United States the Messenger RNA Vaccines and Therapeutics revenue is expected to grow from US$ million in 2024 to US$ million by 2034, at a CAGR of % during the forecast period 2024-2034.
The global key players of Messenger RNA Vaccines and Therapeutics include BioNTech, Moderna, CureVac, Pfizer, Glaxo Smith Kline's, Daiichi Sankyo Company, Intellia Therapeutics, Arcturus Therapeutics and Emmy Vaccine, etc. The global five biggest players hold a share of % in 2024.
Global Messenger RNA Vaccines and Therapeutics Scope and Market Size
Messenger RNA Vaccines and Therapeutics market is segmented in regional and country level, by players, by Type and by Application. Companies, stakeholders, and other participants in the global Messenger RNA Vaccines and Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2018-2034.
For United States market, this report focuses on the Messenger RNA Vaccines and Therapeutics market size by players, by Type and by Application, for the period 2018-2034. The key players include the global and local players, which play important roles in United States.
By Company
BioNTech
Moderna
CureVac
Pfizer
Glaxo Smith Kline's
Daiichi Sankyo Company
Intellia Therapeutics
Arcturus Therapeutics
Emmy Vaccine
CSPC
CanSino
Fosun Pharma
Segment by Type
Self-amplifying
Conventional Non-amplifying
Segment by Application
Cancer
Infectious Diseases
Autoimmune Diseases
Others
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter Introduction
Chapter 1Introduces Messenger RNA Vaccines and Therapeutics definition, global market size, United States market size, United States percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Messenger RNA Vaccines and Therapeutics companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger and acquisition information, etc.
Chapter 5Revenue of Messenger RNA Vaccines and Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 6Americas by type, by application and by country revenue for each segment.
Chapter 7EMEA by type, by application and by region, revenue for each segment.
Chapter 8China by type, by application revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Messenger RNA Vaccines and Therapeutics revenue, gross margin and recent development, etc.
Chapter 11Analyst's Viewpoints/Conclusions
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices